Host immune genetic variations influence the risk of developing acute myeloid leukaemia: results from the NuCLEAR consortium.

Adult Aged Alleles Biomarkers, Tumor Disease Susceptibility / immunology Female Gene Frequency Genetic Predisposition to Disease Genetic Variation Genotype Humans Immunity / genetics Immunomodulation / genetics Leukemia, Myeloid, Acute / etiology Male Middle Aged Polymorphism, Single Nucleotide Risk Assessment Risk Factors Steroids / metabolism

Journal

Blood cancer journal

ISSN: 2044-5385

Titre abrégé: Blood Cancer J

Pays: United States

ID NLM: 101568469

Informations de publication

Date de publication:
16 07 2020

Historique:

received: 29 05 2020

accepted: 06 07 2020

revised: 25 06 2020

entrez: 18 7 2020

pubmed: 18 7 2020

medline: 23 3 2021

Statut: epublish

Résumé

The purpose of this study was to conduct a two-stage case control association study including 654 acute myeloid leukaemia (AML) patients and 3477 controls ascertained through the NuCLEAR consortium to evaluate the effect of 27 immune-related single nucleotide polymorphisms (SNPs) on AML risk. In a pooled analysis of cohort studies, we found that carriers of the IL13

Identifiants

DOI: 10.1038/s41408-020-00341-y PMID: 32678078 PMC: PMC7366925

pubmed: 32678078

doi: 10.1038/s41408-020-00341-y

pii: 10.1038/s41408-020-00341-y

pmc: PMC7366925

doi:

Substances chimiques

Biomarkers, Tumor 0

Steroids 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Pagination

Références

Estey, E. & Dohner, H. Acute myeloid leukaemia. Lancet 368, 1894–1907 (2006).

pubmed: 17126723 doi: 10.1016/S0140-6736(06)69780-8

De Kouchkovsky, I. & Abdul-Hay, M. ‘Acute myeloid leukemia: a comprehensive review and 2016 update’. Blood Cancer J 6, e441 (2016).

pubmed: 27367478 pmcid: 5030376 doi: 10.1038/bcj.2016.50

Dohner, H. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129, 424–447 (2017).

pubmed: 27895058 pmcid: 5291965

Dohner, K. et al. Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. Blood 135, 371–380 (2020).

pubmed: 31826241 pmcid: 6993016 doi: 10.1182/blood.2019002697

Vago, L. & Gojo, I. Immune escape and immunotherapy of acute myeloid leukemia. J. Clin. Invest. 130, 1552–1564 (2020).

pubmed: 32235097 doi: 10.1172/JCI129204 pmcid: 7108895

Shan, W., Ma, X. & Deng, F. Is LukS-PV a novel experimental therapy for leukemia? Gene 600, 44–47 (2017).

pubmed: 27916717 doi: 10.1016/j.gene.2016.11.044

Christopher, M. J. et al. Immune escape of relapsed AML cells after allogeneic transplantation. N. Engl. J. Med. 379, 2330–2341 (2018).

pubmed: 30380364 pmcid: 6322675 doi: 10.1056/NEJMoa1808777

Toffalori, C. et al. Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. Nat. Med. 25, 603–611 (2019).

pubmed: 30911134 doi: 10.1038/s41591-019-0400-z

Muffly, L. et al. Infusion of donor-derived CD8(+) memory T cells for relapse following allogeneic hematopoietic cell transplantation. Blood Adv. 2, 681–690 (2018).

pubmed: 29572391 pmcid: 5873230 doi: 10.1182/bloodadvances.2017012104

Lupianez, C. B. et al. Polymorphisms in host immunity-modulating genes and risk of invasive aspergillosis: results from the AspBIOmics Consortium. Infect. Immun. 84, 643–657 (2015).

pubmed: 26667837 doi: 10.1128/IAI.01359-15

Manuel Sanchez-Maldonado, J. et al. NFKB2 polymorphisms associate with the risk of developing rheumatoid arthritis and response to TNF inhibitors: Results from the REPAIR consortium. Sci. Rep. 10, 4316 (2020).

pubmed: 32152480 pmcid: 7062729 doi: 10.1038/s41598-020-61331-5

Chattopadhyay, S. et al. Eight novel loci implicate shared genetic etiology in multiple myeloma, AL amyloidosis, and monoclonal gammopathy of unknown significance. Leukemia 34, 1187–1191 (2020).

pubmed: 31695157 doi: 10.1038/s41375-019-0619-1

Rios-Tamayo, R. et al. A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: results from the IMMEnSE consortium and meta-analysis. Oncotarget 7, 59029–59048 (2016).

pubmed: 27437873 pmcid: 5312293 doi: 10.18632/oncotarget.10665

Nyholt, D. R. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am. J. Hum. Genet. 74, 765–769 (2004).

pubmed: 14997420 pmcid: 1181954 doi: 10.1086/383251

Li, Y. et al. A functional genomics approach to understand variation in cytokine production in humans. Cell 167, 1099–1110 e1014 (2016).

pubmed: 27814507 doi: 10.1016/j.cell.2016.10.017

Schirmer, M. et al. Linking the human gut microbiome to inflammatory cytokine production capacity. Cell 167, 1897 (2016).

pubmed: 27984736 doi: 10.1016/j.cell.2016.11.046

Ter Horst, R. et al. Host and environmental factors influencing individual human cytokine responses. Cell 167, 1111–1124 e1113 (2016).

pubmed: 27814508 pmcid: 5787854 doi: 10.1016/j.cell.2016.10.018

Moffatt, M. F. et al. A large-scale, consortium-based genomewide association study of asthma. N. Engl. J. Med. 363, 1211–1221 (2010).

pubmed: 20860503 pmcid: 4260321 doi: 10.1056/NEJMoa0906312

Pickrell, J. K. et al. Detection and interpretation of shared genetic influences on 42 human traits. Nat. Genet. 48, 709–717 (2016).

pubmed: 27182965 pmcid: 5207801 doi: 10.1038/ng.3570

Urayama, K. Y. et al. Genome-wide association study of classical Hodgkin lymphoma and Epstein-Barr virus status-defined subgroups. J. Natl. Cancer Inst. 104, 240–253 (2012).

pubmed: 22286212 pmcid: 3274508 doi: 10.1093/jnci/djr516

Bruserud, O. et al. Interleukin 1 receptor antagonist (IL1RA) in acute leukaemia: IL1RA is both secreted spontaneously by myelogenous leukaemia blasts and is a part of the acute phase reaction in patients with chemotherapy-induced leucopenia. Eur. J. Haematol. 57, 87–95 (1996).

pubmed: 8698137 doi: 10.1111/j.1600-0609.1996.tb00495.x

Estrov, Z. et al. Inhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors. Blood 79, 1938–1945 (1992).

pubmed: 1373331 doi: 10.1182/blood.V79.8.1938.1938

Luz-Crawford, P. et al. Mesenchymal stem cell-derived interleukin 1 receptor antagonist promotes macrophage polarization and inhibits B cell differentiation. Stem Cells 34, 483–492 (2016).

pubmed: 26661518 doi: 10.1002/stem.2254

Singh, J. K., Simoes, B. M., Howell, S. J., Farnie, G. & Clarke, R. B. Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells. Breast Cancer Res. 15, 210 (2013).

pubmed: 24041156 pmcid: 3978717 doi: 10.1186/bcr3436

Wang, S. et al. CXCR2 macromolecular complex in pancreatic cancer: a potential therapeutic target in tumor growth. Transl. Oncol. 6, 216–225 (2013).

pubmed: 23544174 pmcid: 3610555 doi: 10.1593/tlo.13133

Ning, Y. et al. The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models. Mol. Cancer Ther. 11, 1353–1364 (2012).

pubmed: 22391039 doi: 10.1158/1535-7163.MCT-11-0915

Jamieson, T. et al. Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis. J. Clin. Invest. 122, 3127–3144 (2012).

pubmed: 22922255 pmcid: 3428079 doi: 10.1172/JCI61067

Schinke, C. et al. IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells. Blood 125, 3144–3152 (2015).

pubmed: 25810490 pmcid: 4432009 doi: 10.1182/blood-2015-01-621631

Waugh, D. J. & Wilson, C. The interleukin-8 pathway in cancer. Clin. Cancer Res. 14, 6735–6741 (2008).

pubmed: 18980965 doi: 10.1158/1078-0432.CCR-07-4843

Sharma, B., Nawandar, D. M., Nannuru, K. C., Varney, M. L. & Singh, R. K. Targeting CXCR2 enhances chemotherapeutic response, inhibits mammary tumor growth, angiogenesis, and lung metastasis. Mol. Cancer Ther. 12, 799–808 (2013).

pubmed: 23468530 doi: 10.1158/1535-7163.MCT-12-0529

Lee, Y. S. et al. Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis. Br. J. Cancer 106, 1833–1841 (2012).

pubmed: 22617157 pmcid: 3364111 doi: 10.1038/bjc.2012.177

Onishi, S. et al. Toll-like receptor 2-mediated interleukin-8 expression in gingival epithelial cells by the Tannerella forsythia leucine-rich repeat protein BspA. Infect. Immun. 76, 198–205 (2008).

pubmed: 17967853 doi: 10.1128/IAI.01139-07

Oliveira-Nascimento, L., Massari, P. & Wetzler, L. M. The role of TLR2 in infection and immunity. Front. Immunol. 3, 79 (2012).

pubmed: 22566960 pmcid: 3342043 doi: 10.3389/fimmu.2012.00079

Sabroe, I. et al. Selective roles for Toll-like receptor (TLR)2 and TLR4 in the regulation of neutrophil activation and life span. J. Immunol. 170, 5268–5275 (2003).

pubmed: 12734376 doi: 10.4049/jimmunol.170.10.5268

Ghosh, T. K. et al. Toll-like receptor (TLR) 2-9 agonists-induced cytokines and chemokines: I. Comparison with T cell receptor-induced responses. Cell Immunol. 243, 48–57 (2006).

pubmed: 17250816 doi: 10.1016/j.cellimm.2006.12.002

Okamoto, M. et al. Toll-like receptors (TLRs) are expressed by myeloid leukaemia cell lines, but fail to trigger differentiation in response to the respective TLR ligands. Br. J. Haematol. 147, 585–587 (2009).

pubmed: 19673881 doi: 10.1111/j.1365-2141.2009.07858.x

Li, K. et al. Targeting acute myeloid leukemia with a proapoptotic peptide conjugated to a Toll-like receptor 2-mediated cell-penetrating peptide. Int. J. Cancer 134, 692–702 (2014).

pubmed: 23852533 doi: 10.1002/ijc.28382

Kuett, A. et al. IL-8 as mediator in the microenvironment-leukaemia network in acute myeloid leukaemia. Sci. Rep. 5, 18411 (2015).

pubmed: 26674118 pmcid: 4682064 doi: 10.1038/srep18411

Vijay, V. et al. Interleukin-8 blockade prevents activated endothelial cell mediated proliferation and chemoresistance of acute myeloid leukemia. Leuk. Res. 84, 106180 (2019).

pubmed: 31299413 pmcid: 6857733 doi: 10.1016/j.leukres.2019.106180

Weidenaar, A. C. et al. High acute myeloid leukemia derived VEGFA levels are associated with a specific vascular morphology in the leukemic bone marrow. Cell Oncol. (Dordr) 34, 289–296 (2011).

doi: 10.1007/s13402-011-0017-9

Aguayo, A. et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 96, 2240–2245 (2000).

pubmed: 10979972 doi: 10.1182/blood.V96.6.2240

Kim, D. H., Lee, N. Y., Lee, M. H. & Sohn, S. K. Vascular endothelial growth factor gene polymorphisms may predict the risk of acute graft-versus-host disease following allogeneic transplantation: preventive effect of vascular endothelial growth factor gene on acute graft-versus-host disease. Biol. Blood Marrow Transplant. 14, 1408–1416 (2008).

pubmed: 19041064 doi: 10.1016/j.bbmt.2008.09.022

Swertz, M. A. et al. The MOLGENIS toolkit: rapid prototyping of biosoftware at the push of a button. BMC Bioinformatics 11(Suppl 12), S12 (2010).

pubmed: 21210979 pmcid: 3040526 doi: 10.1186/1471-2105-11-S12-S12

Wilkinson, M. D. et al. The FAIR Guiding Principles for scientific data management and stewardship. Sci. Data 3, 160018 (2016).

pubmed: 26978244 pmcid: 4792175 doi: 10.1038/sdata.2016.18

Westra, H. J. et al. Systematic identification of trans eQTLs as putative drivers of known disease associations. Nat. Genet. 45, 1238–1243 (2013).

pubmed: 24013639 pmcid: 3991562 doi: 10.1038/ng.2756